公开(公告)号：US20240299537A1

公开(公告)日：2024-09-12

申请号：US18395971

申请日：2023-12-26

申请人： Seqirus UK Limited

发明人： Rino RAPPUOLI ,  Derek O'Hagan ,  Giuseppe DEL GIUDICE

IPC分类号： A61K39/39 ,  A61K39/00 ,  A61K39/12 ,  A61K39/145

CPC分类号： A61K39/39 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/57 ,  C12N2760/16134 ,  C12N2760/16234

摘要： An immunogenic composition comprising: (i) a non-virion influenza virus antigen, prepared from a virus grown in cell culture; and (ii) an adjuvant. Preferred adjuvants comprise oil-in-water emulsions.

公开(公告)号：US11707520B2

公开(公告)日：2023-07-25

申请号：US17072136

申请日：2020-10-16

申请人： Seqirus UK Limited

发明人： Rino Rappuoli ,  Derek O'Hagan ,  Giuseppe Del Giudice

IPC分类号： A61K39/145 ,  A61K39/39 ,  A61K39/12 ,  A61K39/00

CPC分类号： A61K39/39 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/57 ,  C12N2760/16134 ,  C12N2760/16234

摘要： An immunogenic composition comprising: (i) a non-virion influenza virus antigen, prepared from a virus grown in cell culture; and (ii) an adjuvant. Preferred adjuvants comprise oil-in-water emulsions.

公开(公告)号：US11013795B2

公开(公告)日：2021-05-25

申请号：US15739222

申请日：2016-06-24

申请人： Seqirus UK Limited

发明人： Ethan Settembre ,  Philip Dormitzer

IPC分类号： A61K39/145 ,  A61K39/12 ,  A61K39/39 ,  C12N7/00 ,  A61K39/00

摘要： Disclosed herein are influenza vaccine compositions, related preparations and intermediates, formulations, production methods, immunization methods, and use thereof, for achieving improved immune-protection in human subjects. More specifically, non-egg-based influenza vaccines are described, which provide improved antigenic match.

公开(公告)号：US20180196061A1

公开(公告)日：2018-07-12

申请号：US15741816

申请日：2016-07-07

申请人： Seqirus UK Limited

发明人： Yingxia WEN ,  Ethan SETTEMBRE ,  Zihao WANG

IPC分类号： G01N33/68 ,  G01N33/569 ,  A61K39/145 ,  C12N7/00

CPC分类号： G01N33/6848 ,  A61K39/145 ,  C12N7/00 ,  C12N2760/16034 ,  C12N2760/16051 ,  G01N33/56983 ,  G01N2333/11

摘要： The present application discloses stability-indicating potency assays for influenza vaccines.

公开(公告)号：US20170119872A1

公开(公告)日：2017-05-04

申请号：US15290349

申请日：2016-10-11

申请人： Seqirus UK Limited

发明人： Derek O'HAGAN ,  Manmohan SINGH ,  Sung-Yun KWON

IPC分类号： A61K39/145 ,  A61M37/00 ,  A61B17/20 ,  G01N33/68

CPC分类号： A61K39/145 ,  A61B17/205 ,  A61B2017/00004 ,  A61K9/146 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/54 ,  A61K2039/70 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0046 ,  A61M2202/30 ,  C12N2760/16111 ,  C12N2760/16134 ,  C12N2760/16211 ,  C12N2760/16234 ,  G01N33/68 ,  G01N2333/11

摘要： Influenza vaccines are administered using solid biodegradable microneedles. The microneedles are fabricated from the influenza vaccine in combination with solid excipient(s) and, after penetrating the skin, they dissolve in situ and release the vaccine to the immune system. The influenza vaccine is (i) a purified influenza virus surface antigen vaccine, rather than a live vaccine or a whole-virus or split inactivated vaccine (ii) an influenza vaccine prepared from viruses grown in cell culture, not eggs, (iii) a monovalent influenza vaccine e.g. for immunising against a pandemic strain, (iv) a bivalent vaccine, (v) a tetravalent or >4-valent vaccine, (vi) a mercury-free vaccine, or (vii) a gelatin-free vaccine.

公开(公告)号：US20230218526A1

公开(公告)日：2023-07-13

申请号：US18001802

申请日：2021-06-29

申请人： Seqirus UK Limited

发明人： Stephen HUNN

IPC分类号： A61K9/107 ,  A61K39/39 ,  A61K47/14

CPC分类号： A61K9/1075 ,  A61K39/39 ,  A61K47/14 ,  A61K2039/55566

摘要： The present disclosure relates to the method of filtering emulsions at cold temperatures. Specifically, cold filtration of emulsion adjuvants for vaccine manufacture is discussed.

公开(公告)号：US11466257B2

公开(公告)日：2022-10-11

申请号：US16843940

申请日：2020-04-09

申请人： Seqirus UK Limited

发明人： Jens-Peter Gregersen ,  Holger Kost

IPC分类号： C12N7/00 ,  A61K39/145 ,  A61K39/12 ,  A61K39/00

摘要： The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as β-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.

公开(公告)号：US20210205438A1

公开(公告)日：2021-07-08

申请号：US17151840

申请日：2021-01-19

申请人： Seqirus UK Limited

发明人： Christoph HAUSSMANN ,  Frank HAUSCHILD ,  Bjorn JOBST

IPC分类号： A61K39/145 ,  C12N7/00 ,  A61K39/12

摘要： A number of improvements for preparing vaccine antigens from disintegrated influenza viruses are disclosed. A splitting step can be followed by detergent exchange. Splitting can take place in the presence of a buffer with a higher ionic strength and/or in the presence of phosphate buffer.

公开(公告)号：US20200155664A1

公开(公告)日：2020-05-21

申请号：US16452783

申请日：2019-06-26

申请人： Seqirus UK Limited

发明人： Mario CONTORNI ,  Derek O'HAGAN ,  Nicola GROTH

IPC分类号： A61K39/145 ,  C12N7/00 ,  A61K39/12

摘要： Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 μg/ml per strain. In some embodiments the squalene concentration is

公开(公告)号：US20200040040A1

公开(公告)日：2020-02-06

申请号：US16297895

申请日：2019-03-11

申请人： Seqirus UK Limited

发明人： Samuel Ho ,  David Parker ,  Peter Fekkes ,  Ivna De Souza ,  Peter Mason ,  Pirada Suphaphiphat

IPC分类号： C07K14/005 ,  C12N7/00 ,  A61K39/12

摘要： Disclosed herein are methods for increasing protein yield and cellular productivity. Chemical agents facilitate host cell production of biological molecules to increase product yield.